As per the previously agreed terms, Mallinckrodt has paid InfaCare $80 million as upfront payment. InfaCare is eligible for additional milestone payments of up to $345 million on reaching certain ...

Infacare Pharmaceutical Corp has announced a $28 million private placement of its Series B Preferred Stock, led by HealthCare Ventures with participation from Longitude Capital, FirstMark Capital and ...

TREVOSE, Pa., Oct. 27 -- InfaCare Pharmaceutical Corporation, a late stage specialty pharmaceutical company focused on the development of products to treat neonatal diseases, today announced a $28 ...

Discover more of our free reports coverage from other companies within the Drugs - Generic industry. Pro-TD has currently selected Allergan PLC (NYSE: AGN) for due-diligence and potential coverage as ...

Trevose, PA-based InfaCare Pharmaceutical has rounded up $28 million for its Series B, with much of the money earmarked for a late-stage trial. HealthCare Ventures led the round and Harold Werner, a ...

A Bucks County specialty drug company has raised $5.5 million, according to documents filed with the Securities and Exchange Commission. The company, InfaCare Pharmaceutical Corp. of Trevose, is ...

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and InfaCare Pharmaceutical Corporation today announced that they have entered into an agreement under which ...

A pediatric drug developer has raised $3.55 million — the first tranche of a $21.5 million series C Round to advance its drug to treat infantile jaundice or hyperbilirubinemia through a phase 2 ...

Mallinckrodt plc said it plans to acquire Infacare Pharmaceutical Corp., the developer of a late-stage severe jaundice treatment, for $80 million up front plus up to $345 million in potential ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Mallinckrodt PLC is acquiring specialty pharmaceutical firm ...